Registration for a live webinar on 'Rare disease clinical trials: challenges and best practices' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Main points covered
- Proportion of MRSA isolates in Europe
- Antibiotic consumption in different countries
- Consumption of systemic antibacterials, Denmark
- Proportion of carbapenems resistant
- Proportion of fluoroquinolones resistant
- Change in fluoroquinolone use in various countries
- Increasing resistance and increasing use
- Antibiotic use and resistance for Pneumococci
- Azithromycin: selection of resistant S.pneumoniae
- ERSP and consumption of macrolides
- Azithromycin and pneumococci
- Cefuroxim and ciprofloxacin use and resistance
- Antibiotics and resistance: selection
- Selection
- Factors of importance for low antibiotic use (1)
- Factors of importance for low antibiotic use (2)
- Reimbursement influences antibiotic use
- Differential public reimbursement of antimicrobials
- Monthly tetracycline prescription rate, Denmark
- Tetracycline prescription rate and resistance
- Nalidixin-resistant E. Coli and fluoroquinolone use
- Ciprofloxacin: correlation between price and use
- Prize determines the policy and resistance level
- Cost after reimbursement and consumption
- Role of pharmacies
- Consumption of medicine without prescription
- No. of inhabitants per pharmacy and consumption
- Rostering of patients
- Fee-for-service and rostering of patients
- Antibiotic treatment guidelines
- Institute for Rational Pharmacotherapy (IRF)
- Monitoring of antimicrobial use
- National antibiotic barometer
- DANMAP
- Examples from the DANMAP 2007 report (1)
- Examples from the DANMAP 2007 report (2)
- "Ordiprax" on-line database
- Clinical microbiology
- Can GPs help to minimize antibiotic resistance?
- The use of the Strep A test, Denmark
- The use of the Strep A test, Lithuania
- GPs must pursue a rational antibiotic policy
- Registration of antibiotic use
- Are some antibiotics better than others?
- Patient knowledge and press
- A comparative EU study regarding antibiotic use
- A survey of antibiotic leftovers among patients
- Conclusions
- Thank you
Topics Covered
- Factors of importance for low antibiotic use
- Consumption of systemic antibacterials
- Resistant isolates in Europe
- Change in fluoroquinolone use
- Correlation between antibiotic consumption and resistance
- Cefuroxim and ciprofloxacin use and resistance against E. coli
- Selection
- Public reimbursement of antimicrobials
- Tetracycline use
- Ciprofloxacin use in general practice
- Role of pharmacies
- Consumption of medicines without prescription
- Antibiotic treatment guidelines
- Institute for rational pharmacotherapy
- Monitoring of anti-microbial use
- National antibiotic barometer
- Microbiology services
- GPs must pursue a rational antibiotic policy
- Registration of antibiotic use
- Educating the public
- Self-medication
- Public policy to reduce antibiotic resistance
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Frimodt-Møller, N. (2015, July 24). Public policy to reduce antibiotic resistance [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 16, 2024, from https://doi.org/10.69645/QKGS1084.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Niels Frimodt-Møller has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
A selection of talks on Infectious Diseases
Transcript
Please wait while the transcript is being prepared...
0:00
This is a presentation with the title,
Public Policy to Reduce Antibiotic Resistance, by Niels Frimodt-Moller.
I'm from Denmark.
I am a specialist in clinical microbiology and
adjunct professor at Aarhus University in Jutland, Denmark.
I am the head of antibiotic research at
the National Center for Antimicrobials and Infection Control at
the Statens Serum Institute in Copenhagen, Denmark.
0:33
My talk will cover the following points: factors of importance for
low antibiotic use such as examples of
correlation between antibiotic resistance and antibiotic consumption,
factors of importance for antibiotic consumption and how to maintain a low use,
Importance of diagnostic microbiology also at the general practitioner level,
and most of the talk will be based on the Danish experience,
especially because Denmark has a very low use of antibiotics and
a relative low antibiotic resistance level of most human pathogens.
1:13
The first example of antibiotic resistance prevalences is taken from the EARSS homepage.
EARSS is the European Antibiotic Resistance Surveillance System,
which is a system to which all European countries report
antibiotic resistance on selected human pathogens.
This example has shown the prevalence of methicillin-resistant Staphylococcus aureus,
that is MRSA, in all the European countries reporting to EARSS.
And the colors denote the prevalences,
from light green being a low prevalence of below one percent,
and then up through the colors turning more red and finally,
violet to a level of over 50 percent of all Staph.
aureus strains being methicillin resistance.
And as you can see, there is a tendency for
the Northern European countries to have low prevalences,
that is Denmark, Norway, Sweden, and Finland,
have prevalences below five percent together with Holland.
And then the prevalence increases down through Europe to
prevalence rates of between 25 and 50 percent in the southern European countries.
This was in 2007.